Opium consumption and risk of bladder cancer: A case-control analysis

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 610-616

  Hosseini, Seyyed Yousof ^a   Safarinejad, Mohammad Reza ^a   Amini, Erfan ^a   Hooshyar, Hassan ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Addiction; Bladder cancer; Opium; Risk

Indexed keywords

OPIATE;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IRAN; MALE; MIDDLE AGED; NARCOTICS; OPIUM; RISK FACTORS; SEX FACTORS; URINARY BLADDER NEOPLASMS;

EID: 78149388217     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.10.016     Document Type: Article

References (37)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics. CA Cancer J Clin 2001, 51:15-36.
2. Gleockler Ries L., Kosary C., Hankey B., et al. SEER cancer statistics review, 1973-1994 1997, US Department of Health and Human Services, Bethesda (MD), NIH Publication No. 97-2789.
3. American Cancer Society. http://www.cancer.org/downloads/STT/CancerFacts%26Figures2002TM.pdf.
4. Cohen S.M., Shirai T., Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol 2000, 205(Suppl):105-115.
5. Vineis P., Talaska G., Malaveille C., et al. DNA adducts in urothelial cells: Relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 1996, 65((Suppl)6):314.
6. Miyajima A., Nakashima J., Yoshioka K., et al. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997, 76:206-210.
7. Stabolidis N.C. Reprisals. Contribution to the Study of Customs of the Geometric-Archaic Period 1996, University of Crete Press, Rethymnon.
8. Baraka A. Historical aspects of opium, MEJ. Anaesthesiol 1982, 6:289-302.
9. NSDUH 2004. Nonmedical use of prescription pain relievers. The NSDUH Report, 21 May 2004. Office of Applied Studies, Substance Abuse, and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services.
10. Sacerdote P., Limiroli E., Gaspani L. Experimental evidence for immunomodulatory effect of opioids. Immune Mechanisms of Pain and Analgesia, Advances in Experimental Medicine and Biology 2001, 521:106-112. Kluwer Academic Press, New York. H. Machelska, C. Stein (Eds.).
11. Sacerdote P. Opioids and the immune system. Palliat Med 2006, 20(Suppl 1):s9-s15.
12. Vallejo R., de Leon-Casasola O., Benyamin R. Opioid therapy and immunosuppression: A review. Am J Ther 2004, 11:354-365.
13. Risdahl J.M., Khanna K.V., Peterson P.K., et al. Opiates and infection. J Neuroimmunol 1998, 83:4-18.
14. Wang J., Barke R.A., Charboneau R., et al. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005, 174:426-434.
15. Franchi S., Panerai A.E., Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus pituitary adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007, 21:767-774.
16. Nasrollahzadeh D., Kamangar F., Aghcheli K., et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer 2008, 98:1857-1863.
17. Mousavi M.R., Damghani M.A., Haghdoust A.A., et al. Opium and risk of laryngeal cancer. Laryngoscope 2003, 113:1939-1943.
18. Ribeiro-Pinto L.F., Swann P.F. Opium and esophageal cancer: Effect of morphine and opium on the metabolism of N-nitrosodimethylamine and N-nitrosodiethylamine in the rat. Carcinogenesis 1997, 18:365-369.
19. Malaveille C., Friesen M., Camus A.M., et al. Mutagens produced by the pyrolysis of opium and its alkaloids as possible risk factors in cancer of the bladder and oesophagus. Carcinogenesis 1982, 3:577-585.
20. Behmard S., Sadeghi A., Mohareri M.R., et al. Positive association of opium addiction and cancer of the bladder. Results of urine cytology in 3,500 opium addicts. Acta Cytol 1981, 25:142-146.
21. Sadeghi A., Behmard S., Vesselinovitch S.D. Opium: A potential urinary bladder carcinogen in man. Cancer 1979, 43:2315-2321.
22. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision 2000, American Psychiatric Association, American Psychiatric Press, Washington DC.
23. McLellan A.T., Luborksy L., Woody G.E., et al. An improved diagnostic instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis 1980, 168:26-33.
24. Tarlov A.R., Ware J.E., Greenfield S., et al. The Medical Outcomes Study: An application of methods for monitoring the results of medical care. JAMA 1989, 262:925-930.
25. Visher C., McFadden K. A Comparison of Urinalysis Technologies for Drug Testing in Criminal Justice 1991, US National Institute of Justice, Washington, DC.
26. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22:1435-1448.
27. Schabath M.B., Spitz M.R., Zhang X., et al. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis 2000, 21:1163-1166.
28. International agency for research on cancer. WHO Annual Report 1977, World Health Organization.
29. Ghadirian P., Stein G.F., Gorodetzky C., et al. Esophageal cancer studies in the Caspian Littoral of Iran: Some residual results, including opium use as a risk factor. Int J Cancer 1985, 35:593-597.
30. Friesen M., O'Neill I.K., Malaveille C., et al. Substituted hydroxyphenanthrenes in opium pyrolysates implicated in esophageal cancer in Iran: Structures and in vitro metabolic activation of a novel class of mutagens. Carcinogenesis 1987, 8:1423-1432.
31. Friesen M., O'Neill I.K., Malaveille C., et al. Characterization and identification of 6 mutagens in opium pyrolysates implicated in oesophageal cancer in Iran. Mutat Res 1985, 150:177-191.
32. Dahlström B., Mellstrand T., Löfdahl C.G., et al. Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol 1982, 22:535-539.
33. Karlsson M.O., Dahlström B., Eckernäs S.A., et al. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990, 39:275-279.
34. Mitchell I.D., Carlton J.B., Chan M.Y., et al. Noscapine-induced polyploidy in vitro. Mutagenesis 1991, 6:479-486.
35. Gatehouse D.G., Stemp G., Pascoe S., et al. Investigations into the induction of aneuploidy and polyploidy in mammalian cells by the anti-tussive agent noscapine hydrochloride. Mutagenesis 1991, 6:279-283.
36. Pelucchi C., La Vecchia C., Negri E., et al. Smoking and other risk factors for bladder cancer in women. Prev Med 2002, 35:114-120.
37. Sadeghi A., Behmard S. Cancer of the bladder in southern Iran. Cancer 1987, 42:353-356.